Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

High renal threshold for glucose tied to reduced glucose infusion rate in diabetics

28 Dec 2019

Elevation of the renal threshold for glucose (eRTg) appears to lower glucose infusion rate (GIR) and increase glycated haemoglobin (HbA1c) levels, a new study has shown.

Researchers enrolled 67 patients (mean age, 65.5 years; 68.7 percent male) with type 2 diabetes mellitus, who were grouped into two according to baseline eRTg (< vs 180 mg/dL). A hyperinsulinaemic-euglycaemic clamp was used to measure the GIR. Study outcomes were factors affecting eRTg.

The mean HbA1c level was 8.5 percent, while the average estimated glomerular filtration rate (eGFR) was 60.3 mL/min/1.73m2; more than half (52.2 percent) of the patients were taking insulin. The high and low eRTg groups had mean GIR measurements of 5.6±2.3 and 7.9±2.6 mg/kg/min, respectively. This suggested that the former group was insulin resistant, while the latter was sensitive. The difference was statistically significant (p=0.0002).

HbA1c was likewise significantly higher in patients with high eRTg (9.1±1.4 percent vs 7.9±1.3 percent; p=0.0007), as was the proportion of patients on insulin therapy (p=0.0024) and with dyslipidaemia (p=0.0462).

GIR, on the other hand, was significantly yet inversely correlated with eRTg, according to simple linear regression analysis (r, –0.528; p<0.0001).

Complete adjustments for covariates, such as body muscle-to-fat ratio, insulin use, body mass index, hypertension, dyslipidaemia, age, sex, alcohol consumption and current smoking status, did not alter the principal findings. Adjusted models consistently showed GIR as a significant, independent and inverse predictor of eRTg (B, –4.75, 95 percent confidence interval, –7.01 to –2.49; p<0.0001).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.